Kalaris Therapeutics (formerly AlloVir)

United States
Awendaw, South Carolina, United States, 77021

Company profile

Kalaris Therapeutics (formerly AlloVir) company profile

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

Business identity

Contact email
[email protected]
Phone number
(346)772-0319
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2013-01-01, Year

Headquarters

Postal code
77021
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
6
Total equity funding
$401.6M
Last funding
Post IPO Equity / $50M / 2025-12-17
Last equity funding
Post IPO Equity / $50M
Investors
16
Lead investors
2
Founders
2
Articles
115
Exited on
2020-07-30

Founders and investors

Founders

Ann LeenJohn Wilson

Lead investors

Cancer Prevention and Research Institute of TexasFidelity

Investors

FidelityGilead SciencesRedmile GroupRTW InvestmentsSamsara BioCapital